Building on these studies and our previous characterization of tTG in glioblastoma cell lines, we sought to further understand the role of tTG in high grade gliomas (HGGs), specifically in GSCs, as well as how it may be therapeutically targeted, and the mechanism for its up-regulated expression in cancer stem cell (CSC) populations. The gene discussed is TGM2; the disease is cancer.